EVALUATION OF ANTIHYPOXIC ACTIVITY OF ETHYLMETHYLHYDROXIPYRIDINE SUKCINATE IN IN VITRO EXPERIMENTS
Background: The search for potential cardio- and cerebroprotective agents among the derivatives of oxypyridine is topical, since they are proven to contain the compounds with antihypoxic, antioxidant activity, and the original spectrum of neurotropic action of drugs at the level of neurons (anxiolytic, antistress, anticonvulsant, cerebroprotective, antiparkinsonic, antiamnestic and antialcoholic), improve cerebral circulation, inhibit platelet aggregation, increase the antithrombogenic potential of blood, reduce total cholesterol, have a cardioprotective and anti-atherosclerotic effects. The aim of the study: To study the effect of the preparations of ethylmethylhydroxypyridine succinate on the intensity of proteolysis in the extract of the brain tissue and serum of rats in vitro. Materials and methods: The evaluation of antihypoxic activity was performed using a test system for modeling the hypoxia condition in vitro. Results: In the course of the experiment it was established that the number of living cells in group No. 1 (positive control) was 46.82±8.15, the dead number was 23.64±5.52; in group 2 (negative control, 10% formalin solution) – living cells – 32.27±5.18; of the dead – 40.91±7.69; in the group №3 (model of hypoxia) – living cells – 30.91±3.75, dead – 35.45±10.60; in group number 4 (addition of Mexiprim 0.01 mol/l) of living cells – 56.36±6.36, dead cells 31.82±4.05; in group number 5 (addition of Mexiprim 0.01 mole/l in hypoxia), the number of living cells was 53.18±7.17, dead cells 35.45±4.72. On the model of hypoxia in vitro, it was established that the Meksid product significantly increases the viability of cells under conditions of hypoxia in comparison with the control group (53.18±7.17% vs. 30.91±3.75, with p<0.05). Conclusion: It has been established that the proposed method for evaluating antihypoxic activity in vitro, using ethylmethyl hydroxypyridine succinate as a reference substance, is relevant in screening of innovative molecules.